Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome

Techniques in Coloproctology

Volumn 18, Issue 7, 2014, Pages 613-621

  Stasi, C ^a,b   Bellini, M ^c   Bassotti, G ^d   Blandizzi, C ^c   Milani, S ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Health Agency of Tuscany Region   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Brain gut axis; Irritable bowel syndrome; Serotonin; Serotonin receptors

Indexed keywords

ALOSETRON; NARONAPRIDE; ONDANSETRON; PIBOSEROD; PLACEBO; PRUCALOPRIDE; RAMOSETRON; SEROTONIN; SEROTONIN 1 LIKE RECEPTOR; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 1E RECEPTOR; SEROTONIN 1F RECEPTOR; SEROTONIN 1P RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN 5A RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN RECEPTOR; TEGASEROD; UNCLASSIFIED DRUG; VELUSETRAG; SEROTONIN ANTAGONIST;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; BLOOD BRAIN BARRIER; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CONSTIPATION; DIGESTIVE FUNCTION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG PENETRATION; DRUG TOLERABILITY; ENTEROCHROMAFFIN CELL; HUMAN; INTESTINE TRANSIT TIME; IRRITABLE COLON; MOLECULAR INTERACTION; MULTICENTER STUDY (TOPIC); MULTIPLE DRUG DOSE; MUSCLE SPINDLE AFFERENT NERVE; NEUROMODULATION; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN FUNCTION; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TREATMENT DURATION; DRUG EFFECTS; FEMALE; GASTROINTESTINAL MOTILITY; INTESTINE INNERVATION; IRRITABLE BOWEL SYNDROME; MALE; METABOLISM; PHYSIOLOGY; PROGNOSIS; ROLE PLAYING; SEVERITY OF ILLNESS INDEX;

CENTRAL NERVOUS SYSTEM; ENTERIC NERVOUS SYSTEM; FEMALE; GASTROINTESTINAL MOTILITY; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; PROGNOSIS; RECEPTORS, SEROTONIN; ROLE; SEROTONIN ANTAGONISTS; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION;

EID: 84904330824     PISSN: 11236337     EISSN: 1128045X     Source Type: Journal    
DOI: 10.1007/s10151-013-1106-8     Document Type: Review

References (105)

1. Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA (2006) Altered 5-hydroxytryptamine signaling in patients with constipation-and diarrhea-predominant irritable bowel syndrome. Gastroenterology 130:34-43 (Pubitemid 43049833)
2. Stasi C, Rosselli M, Bellini M et al (2012) Altered neuro-endocrine- immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. J Gastroenterol 47:1177-1185
3. Ford AC, Talley NJ, Schoenfeld PS et al (2009) Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 58:367-378
4. Bearcroft CP, Perret D, Farthing MJ (1998) Postprandial plasma 5-hydroxytryptamine in diarrhea-predominant irritable bowel syndrome: a pilot study. Gut 42:42-46 (Pubitemid 28228386)
5. Houghton LA, Foster JM, Whorwell PJ (2003) Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 14:775-782
6. Spiller RC, Jenkins D, Thornley JP (2000) Increased rectal mucosal entero-endocrine cells, T lynphocytes, and increased gut permeability following acute Campilobacter enteris and in post-dysenteric irritable bowel syndrome. Gut 47:804-811
7. Dunlop SP, Coleman NS, Blackshaw E et al (2005) Abnormalities of 5-Hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 3:349-357 (Pubitemid 40488343)
8. Kim DY, Camilleri M (2000) Serotonin: a mediator of the braingut connection. Am J Gastroenterol 95:2698-2709
9. Grundy D, Al-Chaer ED, Aziz Q et al (2006) Fundamentals of neurogastroenterology: basic science. Gastroenterology 130:1391-1411
10. Varnas K, Halldin C, Hall H (2004) Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp 22:246-260 (Pubitemid 38891003)
11. Kirchgessner AL, Liu MT, Raymond JR et al (1996) Identification of cells that express 5-hydroxytryptamine1A receptors in the nervous systems of the bowel and pancreas. J Comp Neurol 364:439-455
12. Fiorica-Howells E, Hen R, Gingrich J et al (2002) 5-HT(2A) receptors: location and functional analysis in intestines of wild-type and 5-HT(2A) knockout mice. Am J Physiol Gastrointest Liver Physiol 282:G877-G893 (Pubitemid 34651633)
13. Hoffman JM, Tyler K, MacEachern SJ et al (2012) Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology 142:844-854
14. Mawe GM, Branchek TA, Gershon MD (1986) Peripheral neural serotonin receptors: identification and characterization with specific antagonists and agonists. Proc Natl Acad Sci USA 83:9799-9803 (Pubitemid 17223444)
15. Gershon MD (1999) Roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 13:15-30
16. Tonini M (2005) 5-Hydroxytryptamine effects in the gut: the 3, 4 and 7 receptors. Neurogastroenterol Motil 17:637-642
17. Pazos A, Prost TA, Palacios JM (1987) Serotonin receptors in the human brain III. Autoradiographic mapping of serotonin-1 receptors. Neuroscience 21:97-122 (Pubitemid 17076866)
18. Pineyro G, Blier P (1999) Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 51:533-591 (Pubitemid 29420214)
19. Wang GD, Wang XY, Zou F et al (2013) Mast cell expression of the serotonin1A receptor in guinea pig and human intestine. Am J Physiol Gastrointest Liver Physiol 304:G855-G863
20. Humprey PP, Hartig P, Hoyer D (1993) A proposed new nomenclature for 5-HT receptors. Trends Pharmacol Sci 14:233-236 (Pubitemid 23172506)
21. Tepper SJ, Rapoport AM, Sheftell FD (2002) Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol 59:1084-1088 (Pubitemid 34755820)
22. Hamel E, Fan E, Linville D et al (1993) Expression of mRNA for the serotonin 5-hydroxytryptamine1D beta receptor subtype in human and bovine cerebral arteries. Mol Pharmacol 44:242-246 (Pubitemid 23252226)
23. Levy FO, Gudermann T, Peres-Reyes E et al (1992) Molecular cloning of a human serotonin receptor (S12) with a pharmacological profile resembling that of the 5-HT1D subtype. J Biol Chem 267:7553-7562
24. Jin H, Oksenberg D, Ashkenazi A et al (1992) Characterization of the human 5-hydroxytryptamine1B receptor. J Biol Chem 267:5735-5738
25. Weinshank RL, Zgombick JM, Macchi MJ et al (1992) Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1Dα and 5-HT1Dβ. Proc Natl Acad Sci USA 89:3630-3634
26. Lowther S, De Paermentier F, Crompton MR et al (1992) The distribution of 5-HT(1D) and 5-HT(lE) binding sites in human brain. Eur J Pharmacol 222:137-142
27. McAllister G, Charlesworth A, Snodin C et al (1992) Molecular cloning of a serotonin receptor from human brain (5HT1E): a fifth 5HT1-like subtype. Proc Natl Acad Sci USA 89:5517-5521
28. Adham N, Kao HT, Schecter LE et al (1993) Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci USA 90:408-412 (Pubitemid 23028871)
29. Molderings GJ, Werner K, Likungu J et al (1990) Inhibition of noradrenaline release from the sympathetic nerves of the human saphenous vein via presynaptic 5-HT receptor similar to the 5-HT(1D) subtype. Naunyn Schmiedebergs Arch Pharmacol 342:371-377 (Pubitemid 20284117)
30. Bax WA, Renzenbrink GJ, Van Heuven-Nolsen D et al (1993) 5-HT receptors mediating contractions of the isolated human coronary artery. Eur J Pharmacol 239:203-210 (Pubitemid 23240160)
31. Tack J, Coulier B, Wilmer A et al (1998) Actions of the 5-hydroxytryptamine 1 receptor agonist sumatriptan on interdigestive gastrointestinal motility in man. Gut 42:36-41 (Pubitemid 28228385)
32. Foguet M, Hoyer D, Pardo LA et al (1992) Cloning and functional characterization of the rat stomach fundus serotonin receptor. EMBO J 11:3481-3487
33. Bubar MJ, Cunningham KA (2006) Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence. Curr Top Med Chem 6:1971-1985 (Pubitemid 44524471)
34. Vane JR (1959) The relative activities of some tryptamine analogues on the isolated rat stomach strip preparation. Br J Pharmacol 14:87-98
35. Cohen ML, Wittenauer LA (1987) Serotonin receptor activation of phos-phoinositide turnover in uterine, fundal, vascular and tracheal smooth muscle. J Cardiovasc Pharmacol 10:176-181 (Pubitemid 17106160)
36. Kursar JD, Nelson DL, Wainscott DB et al (1992) Molecular cloning, functional expression and pharmacological characterisation of a novel serotonin receptor (5-hydroxytryptamine2F) from rat stomach fundus. Mol Pharmacol 42:549-557 (Pubitemid 23027614)
37. Kennet GA, Aiswworth K, Trail B et al (1997) BW 723C86, a 5HT2B receptor antagonist, causes hyperphagia and reduced grooming in rats. Neuropharmacology 36:23-39
38. Gershon MD (2003) Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disord 3:S25-S34
39. Pasqualetti M, Ori M, Castagna M et al (1999) Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain. Neuroscience 92:601-611 (Pubitemid 29268048)
40. Boess FG, Martin IL (1994) Molecular biology of 5HT receptors. Neuropharmacology 33:275-317
41. Pratt GD, Bowery NG, Kilpatrick GJ et al (1990) Consensus meeting agrees distribution of 5-HT3 receptors in mammalian hindbrain. Trends Pharmacol Sci 11:135-137 (Pubitemid 20118001)
42. Thompson AJ, Lummis SC (2007) The 5-HT3 receptor as a therapeutic target. Expert Opin Ther Targets 11:527-540
43. Kidd EJ, Laporte AM, Langlois X et al (1993) 5-HT3 receptors in the rat central nervous system are mainly located on nerve fibres and terminals. Brain Res 612:289-298 (Pubitemid 23167293)
44. Hamon M, Gallissot MC, Menard F et al (1989) 5-HT3 receptor binding sites are on capsaicin-sensitive fibres in the rat spinal cord. Eur J Pharmacol 164:315-322 (Pubitemid 19138638)
45. Takaki M (2003) Gut pacemaker cells: the interstitial cells of Cajal. J Smooth Muscle Res 39:137-161
46. Liu HN, Ohya S, Nishizawa Y et al (2011) Serotonin augments gut pacemaker activity via 5-HT3 receptors. PLoS ONE 6:e24928
47. Marchetti E, Dumuis A, Bockaert J et al (2000) Differential modulation of the 5-HT(4) receptor agonists and antagonist on rat learning and memory. Neuropharmacology 39:2017-2027 (Pubitemid 30645625)
48. King MV, Marsden CA, Fone KC (2008) A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory. Trends Pharmacol Sci 29:482-492
49. Salmon E (2007) A review of the literature on neuroimaging of serotoninergic function in Alzheimer's disease and related disorders. J Neural Transm 114:1179-1185
50. Bockaert J, Claeysen S, Compan V et al (2011) 5-HT(4) receptors, a place in the sun: act two. Curr Opin Pharmacol 11:87-93
51. Madsen K, Haahr MT, Marner L et al (2011) Age and sex effects on 5-HT(4) receptors in the human brain: a [(11)C]SB207145 PET study. J Cereb Blood Flow Metab 31:1475-1481
52. Tack J, Camilleri M, Chang L et al (2012) Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 35:745-767
53. Schoemaker RG, Du XY, Bax WA et al (1993) 5-Hydroxytryptamine stimulates human isolated atrium but not ventricle. Eur J Pharmacol 239:103-105 (Pubitemid 23024988)
54. Oliver KR, Kinsey AM, Wainwright A et al (2000) Localization of 5-HT5A receptor-like immunoreactivity in the rat brain. Brain Res 867:131-142 (Pubitemid 30317389)
55. Pasqualetti M, Ori M, Nardi I et al (1998) Distribution of the 5-HT5A serotonin receptor mRNA in the human brain. Mol Brain Res 56:1-8 (Pubitemid 28271655)
56. Plassat J-L, Boschert U, Amlaiky N et al (1992) The mouse 5-HT5A receptor reveals a remarkable heterogeneity within the 5-HT1D receptor family. EMBO J 11:4779-4786 (Pubitemid 23023420)
57. Grailhe R, Grabtree GW, Hen R (2001) Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution. Eur J Pharmacol 418:157-167 (Pubitemid 32441575)
58. Wesolowski A (2002) In the search for selective ligands of 5-HT5, 5-HT6 and 5-HT7 serotonin receptors. Pol J Pharmacol 54:327-341
59. Thomas DR, Hagan JJ (2004) 5-HT7 receptors. Curr Drug Targets CNS Neurol Disord 3:81-90
60. Tonini M, Vicini R, Cervio E et al (2005) 5-HT(7) receptors modulate peristalsis and accommodation in the guinea pig ileum. Gastroenterology 129:1557-1566 (Pubitemid 41597396)
61. Bülbring E, Lin RC (1985) The effect of intraluminal application of 5-hydroxytryptamine and 5-hydroxytryptophan on peristalsis; the local production of 5-HT and its release in relation to intraluminal pressure and propulsive activity. J Physiol 140:381-407
62. Grider JR (1994) CGRP as a transmitter in the sensory pathway mediating peristaltic reflex. Am J Physiol 266:G1139-G1145
63. Danzebrink RM, Gebhart GF (1991) Evidence that spinal 5-HT1, 5-HT2 and 5-HT3 receptor subtypes modulate responses to noxious colorectal distension in the rat. Brain Res 538:64-75
64. Miftahof R, Akhmadeev NR (2007) Neurochemical bases of visceral nociception: mathematical model. J Theor Biol 249:343-360 (Pubitemid 47632649)
65. Almeida TF, Roizenblatt S, Tufik S (2004) Afferent pain pathways: a neuroanatomical review. Brain Res 1000:40-56 (Pubitemid 38450720)
66. Camilleri M, Coulie B, Tack JF (2001) Visceral hypersensitivity: facts, speculations, and challenges. Gut 48:125-131 (Pubitemid 32042653)
67. Bueno L, Fioramonti J, Delvaux M et al (1997) Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology 112:1714-1743 (Pubitemid 27181399)
68. Keszthelyi D, Troost FJ, Jonkers DM et al (2013) Decreased levels of kynurenic acid in the intestinal mucosa of IBS patients: relation to serotonin and psychological state. J Psychosom Res 74:501-504
69. Stasi C, Bellini M, Costa F et al (2013) Neuroendocrine markers and psychological features in patients with irritable bowel syndrome. Int J Colorectal Dis 28:1203-1208
70. Muller-Lissner SA, Bollani S, Brummer RJ et al (2001) Epidemiological aspects of irritable bowel syndrome in Europe and North America. Digestion 64:200-204 (Pubitemid 34062881)
71. Nakai A, Kumakura Y, Boivin M et al (2003) Sex differences of brain serotonin synthesis in patients with irritable bowel syndrome using alpha-[11C]methyl-L-tryptophan, positron emission tomography and statistical parametric mapping. Can J Gastroenterol 17:191-196 (Pubitemid 36608958)
72. Creed F, Fernandes L, Guthrie E et al (2003) The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 124:303-317 (Pubitemid 36169247)
73. Creed F, Tomenson B, Guthrie E et al (2008) The relationship between somatisation and outcome in patients with severe irritable bowel syndrome. J Psychosom Res 64:613-620 (Pubitemid 351685710)
74. Mayer EA, Naliboff BD, Chang L (2001) Basic pathophysiologic mechanisms in irritable bowel syndrome. Dig Dis 19:212-218 (Pubitemid 34045213)
75. Mertz H (2002) Role of the brain and sensory pathways in gastrointestinal sensory disorders in humans. Gastroenterology 51:i29-i33
76. Whitehead WE, Engel BT, Schuster MM (1980) Irritable bowel syndrome: physiological and psychological differences between diarrhea-predominant and constipation-predominant patients. Dig Dis Sci 25:404-413 (Pubitemid 10124420)
77. Prior A, Maxton DG, Whorwell PJ (1990) Anorectal manometry in irritable bowel syndrome: differences between diarrhoea and constipation predominant subjects. Gut 31:458-462 (Pubitemid 20129448)
78. Simrén M, Abrahamsson H, Bjornsson ES (2001) An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut 48:20-27 (Pubitemid 32042637)
79. Slater BJ, Plusa SM, Smith AN, Varma JS (1997) Rectal hypersensitivity in the irritable bowel syndrome. Int J Colorectal Dis 12:29-32 (Pubitemid 27138355)
80. Harraf F, Schmulson M, Saba L et al (1998) Subtypes of constipation predominant irritable bowel syndrome based on rectal perception. Gut 43:388-394 (Pubitemid 28414921)
81. Steens J, Van Der Schaar PJ, Penning C et al (2002) Compliance, tone and sensitivity of the rectum in different subtypes of irritable bowel syndrome. Neurogastroenterol Motil 14:241-247 (Pubitemid 34639451)
82. Drossman DA, Ringel Y, Vogt BA et al (2003) Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome. Gastroenterology 124:754-761 (Pubitemid 36268492)
83. Baciu MV, Bonaz BL, Papillon E et al (1999) Central processing of rectal pain: a functional MR imaging study. Am J Neuroradiol 20:1920-1924
84. Bonaz B, Baciu M, Papillon E et al (2002) Central processing of rectal pain in patients with irritable bowel syndrome: an fMRI study. Am J Gastroenterol 97:654-661 (Pubitemid 34245894)
85. Suzuki R, Rygh LJ, Dickenson AH (2004) Bad news from the brain: descending 5-HT pathways that control spinal pain processing. Trends Pharmacol Sci 25:613-617 (Pubitemid 39458166)
86. Sharma HS, Cervos-Navarro J, Dey PK(1991) Increased blood-brain barrier permeability following acute short-term swimming exercise in conscious normotensive young rats. Neurosci Res 10:211-221
87. Oatway MA, Chen Y, Weaver LC (2004) The 5-HT3 receptor facilitates at-level mechanical allodynia following spinal cord injury. Pain 110:259-268 (Pubitemid 38953291)
88. Borman RA, Tilford NS, Harmen DW et al (2002) 5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro. Br J Pharmacol 135:1141-1151
89. Beattie DT, Smith JA, Marquess D et al (2004) The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol 143:549-560 (Pubitemid 39524272)
90. Gore S, Gilmore IT, Haigh CG et al (1990) Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment Pharmacol Ther 4:139-144 (Pubitemid 20300402)
91. Steadman CJ, Talley NJ, Phillips SF et al (1992) Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc 67:732-738
92. Goldberg PA, Kamm MA, Setti-Carraro P et al (1996) Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion 57:478-483 (Pubitemid 26385300)
93. Viramontes BE, Camilleri M, McKinzie S et al (2001) Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 96:2671-2676
94. Bharucha AE, Camilleri M, Haydock S et al (2000) Effects of a serotonin 5-HT(4) receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans. Gut 47:667-674
95. De Ponti F, Tonini M (2001) Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs 61:317-332 (Pubitemid 32270041)
96. Camilleri M (2001) Review article: tegaserod. Aliment Pharmacol Ther 15:277-289
97. Frampton JE (2009) Prucalopride. Drugs 69:2463-2476
98. Kozlowski CM, Green A, Grundy D et al (2000) The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut 46:474-480 (Pubitemid 30305810)
99. Lee KJ, Kim NY, Kwon JK et al (2011) Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil 23:1098-1104
100. Schikowski A, Thewissen M, Mathis C et al (2002) Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol Motil 14:221-227 (Pubitemid 34639449)
101. Evans BW, Clark WK, Moore DJ et al (2007) Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev 4:003960
102. Camilleri M, Vazquez-Roque MI, Burton D et al (2007) Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 19:30-38 (Pubitemid 44952776)
103. Johnson DE, Drummond E, Grimwood S et al (2012) The 5-hydroxytryptamine4 receptor agonists prucalopride and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the power of stimulated hippocampal h oscillations. J Pharmacol Exp Ther 341:681-691
104. Manini ML, Camilleri M, Goldberg M et al (2010) Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 22(42-49):e7-e8
105. Hoffman JM, Tyler K, MacEachern SJ et al (2012) Activation of colonic mucosal 5-HT4 receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology 142(844-854):e4